Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects

A promising strategy for cancer immunotherapy is to disrupt key pathways regulating immune tolerance, such as cytotoxic T lymphocyte–associated protein 4 (CTLA-4). However, the determinants of response to anti–CTLA-4 mAb treatment remain incompletely understood. In murine models, anti–CTLA-4 mAbs al...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruocco, Maria Grazia, Pilones, Karsten A., Kawashima, Noriko, Cammer, Michael, Huang, Julie, Babb, James S., Liu, Mengling, Formenti, Silvia C., Dustin, Michael L., Demaria, Sandra
Format: Artigo
Language:Inglês
Published: American Society for Clinical Investigation 2012
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3461908/
https://ncbi.nlm.nih.gov/pubmed/22945631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI61931
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items